Montanaro Asset Management Ltd Sells 32,600 Shares of Balchem Corporation (NASDAQ:BCPC)

Montanaro Asset Management Ltd decreased its position in Balchem Corporation (NASDAQ:BCPC) by 30.3% during the 1st quarter, Holdings Channel reports. The firm owned 74,900 shares of the basic materials company’s stock after selling 32,600 shares during the quarter. Balchem comprises about 3.6% of Montanaro Asset Management Ltd’s holdings, making the stock its 9th biggest position. Montanaro Asset Management Ltd’s holdings in Balchem were worth $12,433,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BCPC. Wells Fargo & Company MN grew its holdings in Balchem by 13.7% in the fourth quarter. Wells Fargo & Company MN now owns 48,365 shares of the basic materials company’s stock valued at $7,883,000 after purchasing an additional 5,846 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Balchem during the fourth quarter valued at $33,000. FMR LLC boosted its stake in shares of Balchem by 16.0% during the fourth quarter. FMR LLC now owns 576,994 shares of the basic materials company’s stock valued at $94,047,000 after acquiring an additional 79,499 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Balchem by 1.9% during the fourth quarter. Bank of Montreal Can now owns 29,024 shares of the basic materials company’s stock valued at $4,731,000 after acquiring an additional 536 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Balchem by 21.2% during the fourth quarter. Invesco Ltd. now owns 228,933 shares of the basic materials company’s stock valued at $37,315,000 after acquiring an additional 40,099 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on BCPC. Wall Street Zen lowered Balchem from a “buy” rating to a “hold” rating in a research note on Saturday, July 26th. HC Wainwright reaffirmed a “buy” rating and set a $189.00 price objective (up previously from $180.00) on shares of Balchem in a research note on Monday, August 4th.

Balchem Stock Performance

NASDAQ BCPC opened at $158.88 on Tuesday. The business’s 50-day moving average price is $159.03 and its 200 day moving average price is $162.12. Balchem Corporation has a twelve month low of $145.70 and a twelve month high of $185.96. The company has a market capitalization of $5.16 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 3.40 and a beta of 0.88. The company has a current ratio of 2.64, a quick ratio of 1.57 and a debt-to-equity ratio of 0.17.

Balchem (NASDAQ:BCPC) last released its quarterly earnings data on Thursday, July 31st. The basic materials company reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.02. The company had revenue of $255.47 million for the quarter, compared to the consensus estimate of $250.31 million. Balchem had a return on equity of 12.41% and a net margin of 14.48%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business posted $1.09 EPS. On average, research analysts predict that Balchem Corporation will post 4.64 earnings per share for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.